They further described an increase of vascular endothelial growth factor (VEGF) expression upon activation of PPARβ/δ and already cautioned against possible negative side effects of agonist treatment in patients susceptible for “angiogenic diseases”, such as elderly persons prone to cancer incidence or diabetic individuals with retinopathies [83]. The gene discussed is PPARD; the disease is cancer.